Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich

The medical center is at the forefront of research in hematologic malignancies, focusing on innovative therapies for conditions such as Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma, and Multiple Myeloma. The center's work in this area aims to improve long-term safety and efficacy of treatments, providing new hope for patients with these challenging diseases.

• Chronic Lymphocytic Leukemia
• Non-Hodgkin's Lymphoma
• Multiple Myeloma
• Acute Myeloid Leukemia
• Acute Lymphocytic Leukemia

Through extensive clinical trials, the center is pioneering the use of targeted therapies and combination treatments to enhance patient outcomes.

Specializing in Multiple Myeloma, the center is conducting groundbreaking studies to evaluate the efficacy of novel drug combinations. By integrating advanced therapeutics such as Daratumumab and Belantamab Mafodotin, the center aims to improve progression-free survival rates and overall treatment efficacy for patients with relapsed or refractory conditions.

• Daratumumab
• Belantamab Mafodotin
• VELCADE (Bortezomib)
• Lenalidomide
• Dexamethasone

The center's research is pivotal in setting new standards for therapeutic protocols in untreated and relapsed multiple myeloma cases.

Focusing on lymphoma treatment, the center is exploring the potential of novel agents like Ibrutinib and Acalabrutinib in improving patient outcomes. These studies aim to provide long-term access to effective treatments and assess their impact on progression-free survival in various lymphoma subtypes.

• B-cell Non-Hodgkin's Lymphoma
• Chronic Graft Versus Host Disease (cGVHD)
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse Large B-Cell Lymphoma

By advancing the understanding of these conditions, the center is contributing significantly to the development of more effective and personalized treatment strategies.